References
- HalpinDMMiravitllesMChronic obstructive pulmonary disease: the disease and its burden to societyProc Am Thorac Soc20063761962316963544
- JensenHHGodtfredsenNSLangePVestboJPotential misclassification of causes of death from COPDEur Respir J200628478178516807258
- JensenMBFenger-GrønMFonagerKOmlandØVindingALHansenJGChronic obstructive pulmonary disease involves substantial health-care service and social benefit costsDan Med J2013601A455723340185
- MiravitllesMMurioCGuerreroTGisbertRCosts of chronic bronchitis and COPD: a 1-year follow-up studyChest2003123378479112628879
- DetournayBPribilCFournierMSCOPE GroupThe SCOPE study: health-care consumption related to patients with chronic obstructive pulmonary disease in FranceValue Health20047216817415164806
- JonesPWHealth status and the spiral of declineCOPD200961596319229709
- HurstJRVestboJAnzuetoAEvaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) InvestigatorsSusceptibility to exacerbation in chronic obstructive pulmonary diseaseN Engl J Med2010363121128113820843247
- Global Initiative for Chronic Obstructive Lung Disease [homepage on the Internet]Global strategy for the diagnosis, management and prevention of COPD2011 [updated Feb 2013]. Available from: http://www.goldcopd.org/Guidelines/guidelines-resources.html
- LeeSYJungKYLeeIKKorean Epilepsy SocietyPrevalence of treated epilepsy in Korea based on national health insurance dataJ Korean Med Sci201227328529022379340
- Korean National Health Insurance Cooperation SeoulAnnual Report of National Health Insurance Statistics, 2008SeoulDivision of statistical analysis, Korean National Health Insurance Cooperation2008 Available from: http://www.nhis.or.kr/portal/site/main/MENU_WBDDG02/Accessed August 2013
- PrescottELangePVestboJSocioeconomic status, lung function and admission to hospital for COPD: results from the Copenhagen City Heart StudyEur Respir J19991351109111410414412
- SinDDAnthonisenNRSorianoJBAgustiAGMortality in COPD: role of comorbiditiesEur Respir J20062861245125717138679
- ManninoDMThornDSwensenAHolguinFPrevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPDEur Respir J200832496296918579551
- GanWQManSFSinDDThe interactions between cigarette smoking and reduced lung function on systemic inflammationChest2005127255856415705996
- BurgelPRPaillasseurJLCaillaudDInitiatives BPCO Scientific CommitteeClinical COPD phenotypes: a novel approach using principal component and cluster analysesEur Respir J201036353153920075045
- de Miguel DiezJCarrasco GarridoPGarcía CarballoMDeterminants and predictors of the cost of COPD in primary care: a Spanish perspectiveInt J Chron Obstruct Pulmon Dis20083470171219281084
- JanssonSAAnderssonFBorgSEricssonAJönssonELundbäckBCosts of COPD in Sweden according to disease severityChest200212261994200212475838
- FaganelloMMTanniSESanchezFFPelegrinoNRLuchetaPAGodoyIBODE index and GOLD staging as predictors of 1-year exacerbation risk in chronic obstructive pulmonary diseaseAm J Med Sci20103391101419926966
- MasaJFSobradilloVVillasanteCCostes de la EPOC en España. Estimación a partir de un estudio epidemiológico poblacional. [Costs of chronic obstructive pulmonary disease in Spain. Estimation from a population-based study.]Arch Bronconeumol20044027279 Spanish14746730
- HoogendoornMFeenstraTLHoogenveenRTAlMMölkenMRAssociation between lung function and exacerbation frequency in patients with COPDInt J Chron Obstruct Pulmon Dis2010543544421191438
- MennPHeinrichJHuberRMKORA Study GroupDirect medical costs of COPD – an excess cost approach based on two population-based studiesRespir Med2012106454054822100535
- BurgePSCalverleyPMJonesPWSpencerSAndersonJAMaslenTKRandomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trialBMJ200032072451297130310807619